ToolGen has submitted a corrected registration statement reflecting the Financial Supervisory Service's request for amendment regarding its 70 billion won rights offering. The existing terms of 777,000 new shares, offering price of 90,200 won per share, and dilution ratio of 8.64 percent remain unchanged.
Proceeds from the offering are planned for patent litigation legal fees of 26.3 billion won and research and development expenses of 29 billion won. Largest shareholder Genexine plans to subscribe only about 10 percent of its allotted shares, reducing its stake from 12.43 percent to 11.54 percent after the offering.
As of end of first quarter 2026, the company held only 5.7 billion won in cash equivalents, with accumulated deficit of 170.5 billion won and persistent operating losses. Current ratio of 1,093.6 percent and debt ratio of 7.7 percent appear healthy but are largely due to asset revaluation.
Key business risks include uncertainties in US CRISPR-Cas9 patent interference proceedings and RNP patent infringement litigation, and potential delays in technology transfer and commercialization as major pipelines remain at preclinical stage. New shares are not subject to lock-up, posing risk of price decline upon listing.
No dividend is available due to absence of distributable profits, and shareholder return policies are to be reviewed only when financial performance materializes. The stock has been designated as a cautionary item 15 times and warning item 2 times in the past three years, indicating high volatility.
[AI Summary]The correction filing allows the rights offering to proceed, but the unchanged conditions mean existing financial difficulties, litigation risks, and low largest shareholder participation persist. With an 8.64 percent dilution scheduled and rapid cash burn combined with potential cost escalation, additional capital raising may be necessary in the future.
KOSDAQ Filing Information
[Correction of Description] Securities Registration Statement (Equity Securities)